The Valley Hospital is now open at 4 Valley Health Plaza in Paramus. (You may need to use 650 Winters Avenue for GPS.) All emergency care is now being provided at this location. Emergency care is no longer available at our Ridgewood campus.
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
ASTEFANIA
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Principal Investigator(s): Amanda J. Podolski, MD
Status: Open and enrolling
B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Principal Investigator(s): Laura Klein, MD
Status: Closed to Enrollment, Patients in Follow-Up
BWEL
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Principal Investigator(s): Laura Klein, MD
Status: Closed to Enrollment, Patients in Follow-Up
COMET
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Principal Investigator(s): Moira Christoudias, MD
Status: Open and enrolling
Destiny – Breast 08
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, No Patients in Follow-Up
EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling
FORCE
Feasibility Of NutRition Counseling For BrEast Cancer Survivors (FORCE Study)
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, Patients in Follow-Up
MonarchE
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, Patients in Follow-Up
NRG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, Patients in Follow-Up
NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling